Golden
Sangamo Therapeutics

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

All edits

Edits on 27 Apr 2019
Mevludin Mešanović
Mevludin Mešanović approved a suggestion from Golden's AI on 27 Apr 2019 3:42 pm
Edits made to:
Infobox (+1 properties)
Edits on 4 Apr 2019
Dawson Sewell
Dawson Sewell edited on 4 Apr 2019 9:09 pm
Edits made to:
Infobox (+6 properties)
Article (+1092/-762 characters)
Further reading (+3 cells) (+40 characters)
Categories (+1 topics)
Related Topics (+2 topics)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 



Sangamo Therapeutics is a biotechnology company developing gene and cell therapies using genetic engineering that is headquartered in Richmond, California and founded in 1995 by Edward Lanphier.

...

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 

Funding

Grant

On February 7, 2018 Sangamo Therapeutics received a grant worth $11 million from the National Institutes of Health (NIH). 

Further reading

Title
Author
Link
Type

AP Exclusive: US scientists try 1st gene editing in the body

Marilynn Marchione

Web

Man 'cured' of HIV through gene editing holds hope for others

Associated Press

Web

Infobox

Categories

Related Topics

Edits on 22 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 Mar 2019 1:14 pm
Edits made to:
Article (+15/-15 characters)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndromeHunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 

Edits on 14 Mar 2019
Dawson Sewell
Dawson Sewell edited on 14 Mar 2019 3:22 pm
Edits made to:
Infobox (+3 properties)
Edits on 25 Feb 2019
Meredith Hanel
Meredith Hanel edited on 25 Feb 2019 5:31 pm
Edits made to:
Companies (+1 rows) (+1 cells) (+6 characters)

Companies

Company
CEO
Location
Products/Services

TxCell







Edits on 22 Feb 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 22 Feb 2019 8:13 pm
Edits made to:
Article (+3/-3 characters)

Article

Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIVHIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 

Edits on 12 Feb 2019
Meredith Hanel
Meredith Hanel edited on 12 Feb 2019 8:34 pm
Edits made to:
Article (+209/-113 characters)

Article

ScientistsSangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo were the first to edit human cells and the first to conductconducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology. Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 





Meredith Hanel
Meredith Hanel edited on 12 Feb 2019 8:00 pm
Edits made to:
Article (+418 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology. Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 





Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 12 Feb 2019 6:41 pm
Edits made to:
Article (+15/-15 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trialsclinical trials with gene edited T cells. In 2018, they initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.

Jude Gomila
Jude Gomila edited on 12 Feb 2019 6:39 pm
Edits made to:
Article (+11/-10 characters)

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. RecentlyIn 2018, wethey initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.

Meredith Hanel
Meredith Hanel edited on 12 Feb 2019 2:34 pm
Edits made to:
Infobox (+9 properties)
Description (+99 characters)
Article (+247 characters)
People (+2 rows) (+4 cells) (+146/-11 characters)
Further reading (+1 rows) (+3 cells) (+154 characters)
Categories (+2 topics)
Related Topics (+2 topics)
Topic thumbnail

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

Article

Scientists at Sangamo were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. Recently, we initiated the first ever in vivo genome editing clinical trials. Sangamo uses zinc finger nuclease technology.



People

Name
Role
Related Golden topics

Heather Turner, JD

Senior Vice President and General Counsel



Sandy Macrae, M.B., Ch.B., Ph.D

CEO



Sandy MacraeStephane Boissel

Executive Vice President Corporate Strategies



Further reading

Title
Author
Link
Type

Man 'cured' of HIV through gene editing holds hope for others



Web

Infobox

Categories

Related Topics

Edits on 8 Jun 2018
Carla Faraguna
Carla Faraguna edited on 8 Jun 2018 11:03 pm
Edits made to:
People (+1 rows) (+2 cells) (+21 characters)
Further reading (+1 rows) (+2 cells) (+115 characters)
Related Topics (+1 topics)
Topic thumbnail

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

People

Name
Role
Related Golden topics

Sandy Macrae

President



Further reading

Author
Title
Link
Type



AP Exclusive: US scientists try 1st gene editing in the body



Related Topics

Edits on 8 Jun 2018
Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 8 Jun 2018 11:00 pm
Edits made to:
Topic thumbnail

 Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

No more activity to show.